ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.
IPO Year: 2017
Exchange: NASDAQ
Website: erytech.com
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the "Autorité des Marchés Financiers" (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities an
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)Once registered, parti
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio
SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)
SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)
SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)
SC 13G - Erytech Pharma S.A. (0001624422) (Subject)
All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy
In February, Erytech Pharma SA (NASDAQ:ERYP) announced its proposed combination with Pherecydes Pharma S.A. In June, Erytech announced that Akkadian initiated proceedings to postpone the vote, scheduled on 23 June, on the merger with Pherecydes. The merger would see Pherecydes absorbed into publicly listed Erytech, with Pherecydes shareholders receiving 15 new Erytech shares for every four of their current shares. Monday, Erytech Pharma responded to what it described as Akkadian Partners' "disinformation," arguing that the investor's challenge to the merger was "based on incomplete information and misleading arguments." Akkadian Partners owns around 5% of Erytech's stock. Erytech warned
Gainers Audacy, Inc. (NYSE:AUD) gained 75.8% to $0.2337 in pre-market trading after gaining around 16% on Wednesday. The company posted upbeat quarterly sales. Polar Power, Inc. (NASDAQ:POLA) gained 68% to $1.73 in pre-market trading after the company unveiled new line of mobile electric vehicle chargers. MMTec, Inc. (NASDAQ:MTC) gained 44.2% to $1.50 in pre-market trading after gaining around 8% on Wednesday. Tivic Health Systems, Inc. (NASDAQ:TIVC) jumped 27.3% to $0.2098 in pre-market trading after gaining 7% on Wednesday. Tivic Health launched a B2B portal. Ampio Pharmaceuticals, Inc. (NYSE:AMPE) surged 24.8% to $0.2521 in pre-market trading after declining around 5% on Wednesday
Gainers Ampio Pharmaceuticals (AMEX:AMPE) stock increased by 38.6% to $0.28 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 4.2 million shares, which is 2348.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. Organogenesis Hldgs (NASDAQ:ORGO) stock increased by 19.04% to $2.5. Today's trading volume for this security ended up closing at 380.2K shares, which is 29.2 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $328.0 million. As per the press release, Q1 earnings came out today. Semler Scientific (NASDAQ:SMLR
Gainers TScan Therapeutics, Inc. (NASDAQ:TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. ClearOne, Inc. (NASDAQ:CLRO) climbed 66.1% to $2.06 after the company announced a special one-time cash dividend of $1.00 per share of common stock, payable May 31 to shareholders of record on May 22, 2023. Ensysce Biosciences, Inc. (NASDAQ:ENSC) gained 52.8% to $5.26 after the company announced completion of PF614-MPAR-101, a clinical study examining its first pain medication with overdose protection, PF614-MPAR. Mobiquity Technologies, Inc. (NASDAQ:MOBQ) climbed 48.5% to $0.2302 after gaining around 7% on Monday
Gainers TScan Therapeutics (NASDAQ:TCRX) stock rose 61.8% to $3.64 during Tuesday's pre-market session. The company's market cap stands at $89.6 million. Erytech Pharma (NASDAQ:ERYP) stock increased by 47.49% to $1.18. The company's market cap stands at $36.5 million. Ensysce Biosciences (NASDAQ:ENSC) stock increased by 42.15% to $4.89. The market value of their outstanding shares is at $6.2 million. Synlogic (NASDAQ:SYBX) stock moved upwards by 23.21% to $0.69. The company's market cap stands at $46.7 million. Novavax (NASDAQ:NVAX) shares rose 20.93% to $9.01. The company's market cap stands at $776.4 million. As per the press release, Q1 earnings came out today. Tactile Systems Tech
Gainers ZyVersa Therapeutics (NASDAQ:ZVSA) shares increased by 31.4% to $2.14 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 8.9 million shares, making up 2630.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.7 million. Jaguar Health (NASDAQ:JAGX) shares increased by 25.92% to $1.02. The current volume of 3.2 million shares is 317.5% of Jaguar Health's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $2.0 million. Erytech Pharma (NASDAQ:ERYP) stock moved upwards by 24.95% to $0.99. The company's market ca
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (NASDAQ:ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech. As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capit
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the "Autorité des Marchés Financiers" (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities an
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent Catalent acquired ERYTECH's U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 millionERYTECH and Catalent to enter into a long-term supply agreement for clinical and commercial supply of eryaspase (GRASPA®)Transaction expected to reduce operating expenses for ERYTECH Transaction brings ERYTECH's cash to approximately EUR 55 million (USD 60 million), and extends cash runway to mid-2024ERYTECH is evaluating valuable strategic options to leverage its ERYCAPS® platform and its development and manufacturing capabilities with complementary assets and/or a broa
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Cambridge, MA (U.S.) and Lyon (France), February 8, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the allowance of a US patent application covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D), a debilitating rare metabolic disease. The claims will also cover methods of treating other indications, including arginine-dependent cancers, septic shock, and angiogenesis-associated diseases. In addition to
ERYTECH Announces the Availabilityof its Half-Year Financial Report 2021 Lyon (France) and Cambridge, MA (U.S.), Septembre 22, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed with the Autorité des Marchés Financiers (AMF) its half-year report for the six-month period ended June 30, 2021. The half-year financial report is available in the Investors section of the Company's corporate website (wwww.erytech.com). About ERYTECH ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood ce
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021 Conference call and webcast on Tuesday, September 21, 2021at 8:30am EDT / 2:30pm CET TRYbeCA-1 Phase 3 trial of eryaspase in second-line metastatic pancreatic cancer fully enrolled since January 2021; on track for final results in Q4 2021 Fast Track designation received for eryaspase in treatment of ALL patients who developed hypersensitivity reactions to pegylated asparaginase; working towards potential BLA submission in this indication before year-end Second dose cohort in Phase 1 Investigator Sponsored Trial (IST) in first-line pancreatic cancer enrolled; determination of Maximum T
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)Once registered, parti
ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021. On-demand Corporate PresentationAn on-demand corporate presentation will be accessible to conference attendees starting on Monday, Sept
ERYTECH to Participate in the Citi 16th Annual BioPharma Conference Cambridge, MA (U.S.) and Lyon (France), August 30, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its participation in the Citi 16th Annual BioPharma Conference and invites investors to join virtually via one-on-one meetings. Citi's 16th Annual BioPharma Conference– September 8 -10, 2021Gil Beyen, Chief Executive Officer, Eric Soyer Chief Financial Officer and Dr. Iman El-Hariry, Chief Medical Officer, will participate in one-on-one meetings on Wednesday Septemb
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)